metastases), and matched normal tissue. Whole exome (WES) and RNA sequencing of tumors was conducted. Patient-derived xenograft (PDX) models were generated from a subset of patients, and the engrafted tumors were analyzed.
INTRODUCTION AND OBJECTIVES: Level 1 evidence shows that mTOR inhibition is associated with clinically significant reductions in tumor size in angiomyolipomas (AMLs) associated with Tuberous Sclerosis. We conducted a phase II, multi-center trial assessing the effectiveness and tolerability of everolimus (EVE) for sporadic AMLs and report the tolerability and adverse effect (AE) data here.
METHODS: We conducted a prospective, phase II clinical trial in patients presenting with >3cm sporadic AMLs who were candidates for surgical or percutaneous intervention. Response was defined as !25% volumetric reduction of the AML. Baseline, 4-and 6-month volumetric analysis was performed by dynamic contrast-enhanced MRI (DCE-MRI). Patients received EVE 10mg for 4 28-day cycles, at which point EVE was discontinued in those with !25% volumetric reduction. Those with !25% volumetric reduction received two additional cycles of EVE. Dose reductions and interruptions were allowed to 5 mg QOD. AEs and patient decisions to withdraw from the trial were categorized. Conservative stopping rules were established for toxicity.
RESULTS: We enrolled 20 patients (median age [ 68) with 21 sporadic AMLs. 11/20 (55%) patients completed 4 cycles of EVE, and 7/ 20 (35%) completed 6 cycles. Efficacy was demonstrated, with 10/16 (62.5%) patients exhibiting !25% reduction in tumor volume at 4 months and 8/12 (66.6%) patients exhibiting !25% reduction in tumor volume at 6 months. 4/20 (20%) patients were withdrawn due to predefined toxicities, including grade 3 mucositis, grade 1 pneumonitis, grade 2 pneumonitis, and grade 2 hyperglycemia. Dose reductions were required in 6/20 (30%) patients. 2 (10%) patients required two dose reductions, and 4 (20%) patients required a single dose reduction. 19/20 (95%) of patients experienced at least one grade 2 AE during the trial. 5/20 (25%) patients had grade 3 toxicities (oral mucositis in 3 patients, hyperglycemia in 1 patient, and UTI in 1 patient) which resolved upon discontinuation or dose reduction of EVE. Of the 8/20 (40%) patients who withdrew due to personal preference, a mean of 13.75 AEs were experienced, mainly grade 1 and 2. The most common AEs during the trial included oral mucositis (70%), increased ALT (55%), hyperlipidemia (55%), increased AST (50%), anemia (50%), hyperglycemia (40%), and fatigue (40%).
CONCLUSIONS: EVE was associated with a high rate of treatment termination due to patient preference or protocol-defined AEs. Patients appear to be less willing to tolerate the side-effect profile of EVE for benign lesions such as AMLs as they be might for metastatic renal cell carcinoma. METHODS: We identified 113 mRCC patients who received first-line therapy of sunitinib or sorafenib between January 2006 to December 2016 in Renji Hospital affiliated to Shanghai Jiao Tong University school of medicine. In this retrospective single-center research, PBRM1, BAP1 and SETD2 expression was assessed by immunohistochemistry, the Kaplan-Meier method was used to estimate the progression free survival (PFS) and overall survival (OS), log-rank test was used to compare the survival outcomes between patients with low and high SETD2, PBRM1 and BAP1 expression level, and cox proportional hazard regression model was used to estimate the prognostic value. Prognostic accuracy was determined using Harrell concordance index and ROC analysis.
RESULTS CONCLUSIONS: Expression of SETD2 combined with PBRM1 could be significant prognostic factor for mRCC patients receiving target therapy while BAP1 could not. We also proved that SETD2 combined with PBRM1 could improve predictive accuracy for overall survival outcomes. SETD2 and PBRM1 are not only potential biomarkers for treatment for mRCC, but also play an important role in controlling the development and predicting prognosis of target treatment in mRCC. INTRODUCTION AND OBJECTIVES: Holmium:YAG lasers fragment urinary stones through both photothermal effects and generation of cavitation bubbles. Improved synthetic stone mass loss has been demonstrated for laser lithotripsy in the presence of stone targeting microbubbles. The present study hypothesizes that lipid-shell microbubbles with stone-binding properties also create smaller and more numerous stone fragments through enhancement of cavitation effects.
Source of Funding
METHODS: Synthetic hydroxyapatite (HA) discs [13 mm x 1.8 mm] were fragmented with a pulsed 100W Holmium:YAG laser (1000mm fiber) along a circular path 9 mm in diameter over 60 seconds (Figure) . This was performed with (n[10) and without (n[10) targeting microbubbles composed of a lipid-shell with calcium-binding moieties and perfluoroalkane gas. HA discs were weighed dry before and after a single lithotripsy session in which all fragments > 0.5mm were recovered using a sieve mesh. Fragments were digitally photographed on a standardized stage such that number, size, and volume of fragments could be calculated using ImageJ software. Comparisons were made with a 2-tailed Mann-Whitney U-test.
RESULTS: The mean number of stone fragments was 4.6AE1.6 for control vs 6.9AE1.9 (p[0.02) for targeting microbubbles. The median fragment volume was 31 mm 3 (IQR 21-67) for control and 26 mm 3 (IQR 10-45) for targeting microbubbles (p[0.041). Mean stone mass loss was 3.9AE3 mg for control vs. 11.3AE5 mg for targeting microbubbles (p[0.045).
CONCLUSIONS: Targeting microbubbles fragment HA stones into smaller and more numerous fragments during in vitro Holmium:YAG laser lithotripsy in addition to causing increased mass loss.
Stone targeting microbubbles, when used as an adjunct with Holmium laser lithotripsy, have the potential to reduce operative time, increase the number and decrease the size of stone fragments, and thereby result in higher stone-free rates and improved patient outcomes. The risk of thermal damage with laser lithotripsy within the ureter is hypothesized to be even greater than in a renal calyx given the smaller volume of fluid adjacent to the laser fiber. The aim of this study was to experimentally measure temperature and calculate thermal dose for a range of laser power and irrigation parameters in a simulated ureteral model. METHODS: The experimental system consisted of a rounded glass tube (inner diameter 6 mm/length 130 mm) simulating a ureter that ends with a 19 mm sphere simulating a renal pelvis. A 242 mm laser fiber (Flexiva, Boston Scientific) was inserted through a ureteroscope (Lithovue, Boston Scientific) and positioned 60 mm away from the simulated pelvis wall. Real time temperature was recorded using two wire thermocouples; one at the level of the ureteroscope and another in the simulated pelvis. The model was placed in a water bath maintained at 37 C. Irrigation with room temperature fluid was provided at 25,12, or 6 mL/min. Laser energy was applied (pulse 120; Lumenis) for 60 seconds. Thermal dose for each trial was calculated based on Dewey and Sapareto t43 equivalence calculations. Thermal toxicity (cell death) was considered attained when t43[ 120 minutes, the equivalent of maintain 43 C for 120 minutes. The probability of exceeding t43 [ 120 equivalent minutes was determined for strategically selected power levels and irrigant flow rates in order to map the safety margin. Each experiment was repeated 5 times.
Source of
RESULTS: Thermal dose within the ureter for each parameter pair (power, irrigation rate) is represented by a circle in Figure 1 . The percentage of trials that exceeded t43[ 120 minutes is indicated on each circle. Temperature in the renal pelvis was not elevated by laser lithotripsy in the ureter.
CONCLUSIONS: We have defined a thermal safety threshold between safe and unsafe laser/irrigation parameter set pairs. Further studies are needed to map out the safety thresholds for other locations within the urinary tract. This methodology will also provide a framework in which to assess effectiveness of various strategies to control and mitigate thermal dose.
